{"url_path":"/sec/elvn/8-k/2026-06-12/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1672619/0001193125-26-269635-index.html","accession_number":"0001193125-26-269635","cik":"0001672619","ticker":"ELVN","issuer_name":"Enliven Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1672619/0001193125-26-269635-index.html","primary_entity_key":"0001672619","primary_entity_name":"Enliven Therapeutics, Inc."},"word_count":140,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\nSee the Exhibit Index below, which is incorporated by reference herein.\n\nEXHIBIT INDEX\n\n \n\nExhibit\n\nNo.\n\n  \nDescription\n\n 1.1\n  \n[Underwriting Agreement, dated as of June 11, 2026, among Enliven Therapeutics, Inc. and the Representatives.](d152122dex11.htm)\n\n 4.1\n  \n[Form of Pre-Funded Warrant.](d152122dex41.htm)\n\n 5.1\n  \n[Opinion of Wilson Sonsini Goodrich & Rosati, P.C.](d152122dex51.htm)\n\n23.1\n  \n[Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1).](d152122dex51.htm)\n\n99.1\n  \n[Press Release dated June 11, 2026.](d152122dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nEnliven Therapeutics, Inc.\n\nDate: June 12, 2026\n \n\n \nBy:\n \n\n/s/ Benjamin Hohl\n\n \n\n \nName:\n \nBenjamin Hohl\n\n \n\n \nTitle:\n \nChief Financial Officer and Head of Corporate Development"}